Fig. 4From: Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2a Fitting window for 7-day rolling averaged data for all incidence. b–f SIR model with multi-dose vaccine and median parameter values from MCMC fitting analysis overlayed on 7-day rolling averaged incidence data for different vaccinations statesBack to article page